drugset / Trial / NCT00550043
A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to understand the safety and tolerability of INCB018424 in patients with rheumatoid arthritis
Timeline
- Start
- 2007-10
- Primary completion
- 2008-09
- Completion
- 2008-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ruxolitinib | Small molecule | 5 mg | — |
| Subject | Ruxolitinib | Small molecule | 15 mg | — |
| Subject | Ruxolitinib | Small molecule | 25 mg | — |
| Subject | Ruxolitinib | Small molecule | 50 mg | — |